Tryptophan 2,3 Dioxygenase - Pipeline Review, H1 2020

Tryptophan 2,3 Dioxygenase - Pipeline Review, H1 2020

Summary

According to the recently published report 'Tryptophan 2,3 Dioxygenase - Pipeline Review, H1 2020'; Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) pipeline Target constitutes close to 12 molecules.

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Tryptophan 2, 3-dioxygenase is an enzyme that plays a critical role in tryptophan metabolism by catalyzing the first and rate-limiting step of the kynurenine pathway. It has specificity towards tryptamine and derivatives including D- and L-tryptophan, 5-hydroxytryptophan and serotonin.

The report 'Tryptophan 2,3 Dioxygenase - Pipeline Review, H1 2020' outlays comprehensive information on the Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 3, 7 and 2 respectively. Report covers products from therapy areas Oncology, Central Nervous System and Genito Urinary System And Sex Hormones which include indications Melanoma, Solid Tumor, Bladder Cancer, Colon Carcinoma, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Glioblastoma Multiforme (GBM), Head And Neck Cancer, Kidney Cancer (Renal Cell Cancer), Lung Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer and Parkinson's Disease.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11)
- The report reviews Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope